Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia.
Regina M MyersYimei LiAllison Barz LeahyDavid M BarrettDavid Trent TeacheyColleen CallahanChristina C FasanoSusan R RheingoldAmanda M DiNofiaLisa WrayRichard AplencDiane BaniewiczHongyan LiuPamela A ShawEdward PequignotKelly D GetzJennifer L BrogdonAndrew D FesnakDonald L SiegelMegan M DavisChelsie BartoszekSimon F LaceyElizabeth O HexnerAnne ChewGerald B WertheimBruce L LevineCarl H JuneStephan A GruppShannon L MaudePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
HuCART19 achieved durable remissions with long-term persistence in children and young adults with relapsed or refractory B-ALL, including after failure of prior CAR T-cell therapy.
Keyphrases
- acute lymphoblastic leukemia
- young adults
- cell therapy
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- induced apoptosis
- multiple myeloma
- hodgkin lymphoma
- diffuse large b cell lymphoma
- stem cells
- mesenchymal stem cells
- hiv infected
- oxidative stress
- endoplasmic reticulum stress
- cancer therapy
- bone marrow
- drug delivery
- cell proliferation